ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,994.57
      -0.76%
      US Tech 100
      20,692.80
      -0.15%
      Dow Jones
      44,421.91
      -0.28%
      Brent Oil
      75.065
      -0.39%
      Bitcoin
      98,695.29
      -2.69%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Oruka Therapeutics Inc (ORKA) Quote

      Oruka Therapeutics Inc

      Oruka Therapeutics Inc (ORKA)

      NASDAQ
      13.70
      0.25
      (1.86%)
      Closed February 03 4:00PM
      Delayed by 15 minutes
      12.00
      -1.70
      ( -12.41% )
      Pre Market: 4:51AM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      12.00
      Bid
      10.06
      Ask
      21.92
      Volume
      213
      0.00 Day's Range 0.00
      10.95 52 Week Range 31.13
      Market Cap
      419.983M
      Previous Close
      13.70
      Open
      -
      Last Trade
      1
      @
      13.99
      Last Trade Time
      04:51:10
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      312,560
      Shares Outstanding
      34,998,550
      Dividend Yield
      -
      PE Ratio
      -89.84
      Earnings Per Share (EPS)
      -0.15
      Revenue
      -
      Net Profit
      -5.34M

      About Oruka Therapeutics Inc

      ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome ... ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Show more

      Sector
      In Vitro,in Vivo Diagnostics
      Industry
      In Vitro,in Vivo Diagnostics
      Website
      www.orukatx.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Oruka Therapeutics Inc is listed in the In Vitro,in Vivo Diagnostics sector of the NASDAQ with ticker ORKA. The last closing price for Oruka Therapeutics was $13.70. Over the last year, Oruka Therapeutics shares have traded in a share price range of $ 10.95 to $ 31.13.

      Oruka Therapeutics currently has 34,998,550 shares outstanding. The market capitalization of Oruka Therapeutics is $479.48 million. Oruka Therapeutics has a price to earnings ratio (PE ratio) of -89.84.

      Ask ADVFN Intelligence (AI)

      ORKA Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities

      January 24 2025
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      January 24 2025
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      January 24 2025
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      January 24 2025
      Edgar (US Regulatory)

      Form 8-K - Current report

      December 19 2024
      Edgar (US Regulatory)

      Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

      Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial...

      December 19 2024
      GlobeNewswire Inc.

      Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

      MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...

      December 18 2024
      GlobeNewswire Inc.

      Form EFFECT - Notice of Effectiveness

      November 27 2024
      Edgar (US Regulatory)

      Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

      November 21 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      November 21 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.665.8201058201111.3414.1110.9519551612.78106287CS
      4-8.32-40.944881889820.3220.8810.9532122413.7486102CS
      12-14.33-54.424610710226.3327.5110.9531256018.94905199CS
      26-17-58.62068965522931.1310.9520583620.606033CS
      52-17-58.62068965522931.1310.9520583620.606033CS
      156-17-58.62068965522931.1310.9520583620.606033CS
      260-17-58.62068965522931.1310.9520583620.606033CS

      ORKA - Frequently Asked Questions (FAQ)

      What is the current Oruka Therapeutics share price?
      The current share price of Oruka Therapeutics is $ 12.00
      How many Oruka Therapeutics shares are in issue?
      Oruka Therapeutics has 34,998,550 shares in issue
      What is the market cap of Oruka Therapeutics?
      The market capitalisation of Oruka Therapeutics is USD 479.48M
      What is the 1 year trading range for Oruka Therapeutics share price?
      Oruka Therapeutics has traded in the range of $ 10.95 to $ 31.13 during the past year
      What is the PE ratio of Oruka Therapeutics?
      The price to earnings ratio of Oruka Therapeutics is -89.84
      What is the reporting currency for Oruka Therapeutics?
      Oruka Therapeutics reports financial results in USD
      What is the latest annual profit for Oruka Therapeutics?
      The latest annual profit of Oruka Therapeutics is USD -5.34M
      What is the registered address of Oruka Therapeutics?
      The registered address for Oruka Therapeutics is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
      What is the Oruka Therapeutics website address?
      The website address for Oruka Therapeutics is www.orukatx.com
      Which industry sector does Oruka Therapeutics operate in?
      Oruka Therapeutics operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      EVAXEvaxion Biotech AS
      $ 4.45
      (85.42%)
      		8.62M
      TNFATNF Pharmaceuticals Inc
      $ 0.98
      (34.62%)
      		100
      PLTUDirexion DAily PLTR Bull 2X Shares
      $ 43.70
      (32.46%)
      		82.02k
      PTIRGraniteShares 2X Long PLTR Daily ETF
      $ 205.20
      (32.12%)
      		56.12k
      IVVDInvivyd Inc
      $ 1.36
      (28.30%)
      		8.86M
      UPCUniverse Pharmaceuticals Inc
      $ 0.3007
      (-27.96%)
      		44.9k
      UOKAMDJM Ltd
      $ 0.1731
      (-27.27%)
      		542.63k
      BCTXBriaCell Therapeutics Corporation
      $ 3.67
      (-27.18%)
      		16.79k
      EJHE Home Household Service Holdings Ltd
      $ 0.7652
      (-24.98%)
      		35.37k
      TENXTenax Therapeutics Inc
      $ 4.48
      (-24.71%)
      		98
      IVVDInvivyd Inc
      $ 1.36
      (28.30%)
      		8.86M
      EVAXEvaxion Biotech AS
      $ 4.45
      (85.42%)
      		8.62M
      BHATBlue Hat Interactive Entertainment Technology
      $ 0.0405
      (-12.34%)
      		2.34M
      TNXPTonix Pharmaceuticals Holding Corporation
      $ 0.163
      (-16.37%)
      		2.24M
      RIMEAlgorhythm Holdings Inc
      $ 0.0268
      (0.37%)
      		1.78M

      Discussion

      View Full Feed
      stocup stocup 2 minutes ago
      Well, I guess I can forget about those.10’s
      I thought I might get.
      RDGL
      weedtrader420 weedtrader420 4 minutes ago
      China not taking America’s tariffs serious because our markets are crashing when Trump puts tariffs on them. when China put tariffs on us,China stock market goes up.wtf
      BTCUSD
      highlandernew highlandernew 9 minutes ago
      🔴🔴AMC at ¢0.30 cents: OBV goes ◼️UP-or-DOWN◼️ today?:

      *** Click on images to zoom? (if needed?) ***

      https://investorshub.advfn.com/uimage/uploads/2025/1/20/wlgieAMC_7Xs.png
      https://invest
      AMC
      PickStocks PickStocks 11 minutes ago
      Only if Plan 6 was approved....but it was not......
      COOP
      KenKong KenKong 12 minutes ago
      Sue to hide their corruption?!?!
      FNMA
      dennisdave dennisdave 12 minutes ago
      taking 16 weeks => should be 6 weeks
      NWBO
      Seminole Red Seminole Red 18 minutes ago
      WASHINGTON—Sen. Brian Schatz (D., Hawaii) said he would place a “blanket hold” on all of President Trump’s State Department nominees until the administration’s attack on the leading U.S. foreign-assistance agency ends, a move that threatens to stall Trump’s ability to get his foreign-policy team in
      jackson73 jackson73 23 minutes ago
      EVAX highs ;-)
      EVAX
      WHITTENHALLJR WHITTENHALLJR 23 minutes ago
      Todays the day? I ether make $$$$ or lose it all 🤣
      CLHI
      St. Sauvage St. Sauvage 24 minutes ago
      Big style="font-size: 1em"Belief in the basin/rift, they just chose the wrong spot...
      style="font-size: 1em"

      style="font-size: 1em"Most bailing out as they believe can make $ in market over next 4-5 months and then jump back in before next well...
      st
      RECAF
      SkeBallLarry SkeBallLarry 24 minutes ago
      El Salvador offers to jail ‘dangerous’ US citizens >

      and accept criminal illegal migrants from any country
      ((( Not sure just-what I think of this )))
      https://nypost.com/2025/02/03/us-news/marco-rubio-says-el-salvador-offers-to-accept-deportees-from-us-of-any-nationality
      SkeBallLarry SkeBallLarry 26 minutes ago
      El Salvador offers to jail ‘dangerous’ US citizens >

      and accept criminal illegal migrants from any country
      ((( Not sure just-what I think of this )))
      https://nypost.com/2025/02/03/us-news/marco-rubio-says-el-salvador-offers-to-accept-deportees-from-us-of-any-nationality
      tbonaces80 tbonaces80 26 minutes ago
      Squeeze them shorte
      LAES
      SkeBallLarry SkeBallLarry 27 minutes ago
      El Salvador offers to jail ‘dangerous’ US citizens >

      and accept criminal illegal migrants from any country
      ((( Not sure just-what I think of this )))
      https://nypost.com/2025/02/03/us-news/marco-rubio-says-el-salvador-offers-to-accept-deportees-from-us-of-any-nationality
      SkeBallLarry SkeBallLarry 30 minutes ago
      El Salvador offers to jail ‘dangerous’ US citizens >

      and accept criminal illegal migrants from any country
      ((( Not sure just-what I think of this )))
      https://nypost.com/2025/02/03/us-news/marco-rubio-says-el-salvador-offers-to-accept-deportees-from-us-of-any-nationality
      The Danish Dude The Danish Dude 32 minutes ago
      OWNERSHIP, CONTROL and LEASE

      I wrote a BIG POST a year ago

      https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175307408

      Where I answered the question:

      REGARDING SUBLEASE. WHO OWNS SAWSTON? WHAT IS THE RELATIONSHIP BETWEEN NWBO
      CDMO NWBO
      Stino2 Stino2 37 minutes ago
      stil 168,212,237 short 😪
      TNXP
      MadScholar1 MadScholar1 41 minutes ago
      Just a question, biowin. On the assumption that KKR owns the rights to BioAmber's technology, is it possible they are licensing the technology to other companies? I'm just wondering. It seems like there's more than one company developing products using BioAmber's technology. I can't see how LCYBioSc
      Superhoops Superhoops 43 minutes ago
      This explains a lot... you're one of them aren't you?...
      MCIC
      diggitydoodle diggitydoodle 46 minutes ago
      Still no news. No updated fins. Nothing.
      But, there is the pumpers constant blabbering that everything here is going as planned and our CEO is great. So, there is that!
      🤣🤣🤣🤣🤣🤣🤣🤣
      GLTA!
      RNVA!!$$??????????????
      RNVA
      dennisdave dennisdave 46 minutes ago
      Krisgo,

      If you want to know the reason then read this post I posted on Oct 16 2024 and in there is your answer
      Anyway, it should be no surprise that they are (as we must always believe Senti about bad news delays) inspection-delayed.
      To be fair we don't know if its beca
      NWBO
      WooptdooU WooptdooU 48 minutes ago
      Hopelessly hopeful pennylongs running out of time...eom
      LWLG
      St. Sauvage St. Sauvage 50 minutes ago



      Some may say, we are either on a one way, doomed space voyage to the planet Jupiter or we're going to be sittin' and shitin' in Tall Cotton.
      Me, I'm partial to
      MNKD

      Your Recent History

      NASDAQ
      ORKA
      Oruka Therapeutics
      AQSE
      TTAU
      Tectonic Gold
      BIT
      S24917
      SG ISSUER
      BOV
      BFCG39
      First Trust Natural Gas ...
      BIT
      UC6Y6U
      Unicredit Bank
      CSE
      ROMJ.WT
      Rubicon Organics
      BIT
      METE
      ETF
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads